[Sixty years of expensive drugs: from an ad-hoc policy to the structural study of efficiency].
The financing of expensive drugs is not a problem that started yesterday. This article describes the historical developments since the introduction of expensive streptomycin in 1947. The shift from ad-hoc financial compensation of the hospitals to the contemporary financing structure, in which a study of the efficiency is required, is explained. The increasing number of expensive drugs and the increasing extramural use will exert ever-increasing pressure on the overall system of medical care.